Patents by Inventor Brian SPARLING

Brian SPARLING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING NEUROLOGICAL DISORDERS
    Publication number: 20240294492
    Abstract: The present disclosure relates to compounds of Formula (I). and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.
    Type: Application
    Filed: April 5, 2024
    Publication date: September 5, 2024
    Inventors: Paul Dransfield, Dilinie Fernando, James Harvey, Brian Sparling, John Stellwagen, Zhihua Ma, Anne-Marie Beausoleil, Ryan Hudson
  • METHODS OF TREATING NEUROLOGICAL DISORDERS
    Publication number: 20240246928
    Abstract: The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.
    Type: Application
    Filed: December 1, 2023
    Publication date: July 25, 2024
    Inventors: Paul Dransfield, Dilinie Fernando, James Harvey, Brian Sparling, John Stellwagen, Zhihua Ma, Anne-Marie Beausoleil, Ryan Hudson
  • Methods of treating neurological disorders
    Patent number: 11993580
    Abstract: The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.
    Type: Grant
    Filed: December 1, 2023
    Date of Patent: May 28, 2024
    Assignee: Neumora Therapeutics, Inc.
    Inventors: Paul Dransfield, Dilinie Fernando, James Harvey, Brian Sparling, John Stellwagen, Zhihua Ma, Anne-Marie Beausoleil, Ryan Hudson
  • Bicyclic sulfonamide compounds as sodium channel inhibitors
    Patent number: 9458152
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: October 4, 2016
    Assignee: Amgen Inc.
    Inventors: Matthew Weiss, Alessandro Boezio, Christiane Boezio, John R. Butler, Margaret Yuhua Chu-Moyer, Erin F. Dimauro, Thomas Dineen, Russell Graceffa, Angel Guzman-Perez, Hongbing Huang, Charles Kreiman, Daniel La, Isaac E. Marx, Benjamin Charles Milgram, Hanh Nho Nguyen, Emily Anne Peterson, Karina R. Vaida, Brian Sparling
  • BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS
    Publication number: 20160046626
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: October 22, 2015
    Publication date: February 18, 2016
    Inventors: Matthew WEISS, Alessandro BOEZIO, Christiane BOEZIO, John R. BUTLER, Margaret Yuhua CHU-MOYER, Erin F. DIMAURO, Thomas DINEEN, Russell GRACEFFA, Angel GUZMAN-PEREZ, Hongbing HUANG, Charles KREIMAN, Daniel LA, Isaac E. MARX, Benjamin Charles MILGRAM, Hanh Nho NGUYEN, Emily Anne PETERSON, Karina R. VAIDA, Brian SPARLING
  • Bicyclic sulfonamide compounds as sodium channel inhibitors
    Patent number: 9212182
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: December 15, 2015
    Assignee: Amgen Inc.
    Inventors: Matthew Weiss, Alessandro Boezio, Christiane Boezio, John R. Butler, Margaret Yuhua Chu-Moyer, Erin F. Dimauro, Thomas Dineen, Russell Graceffa, Angel Guzman-Perez, Hongbing Huang, Charles Kreiman, Daniel La, Isaac E. Marx, Benjamin Charles Milgrim, Hanh Nho Nguyen, Emily Peterson, Karina Romero, Brian Sparling
  • BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS
    Publication number: 20140371201
    Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: June 11, 2014
    Publication date: December 18, 2014
    Inventors: Matthew WEISS, Alessandro BOEZIO, Christiane BOEZIO, John R. BUTLER, Margaret Yuhua CHU-MOYER, Erin F. DIMAURO, Thomas DINEEN, Russell GRACEFFA, Angel GUZMAN-PEREZ, Hongbing HUANG, Charles KREIMAN, Daniel LA, Isaac E. MARX, Benjamin Charles MILGRIM, Hanh Nho NGUYEN, Emily PETERSON, Karina ROMERO, Brian SPARLING